Showing 1 - 20 results of 106 for search '"Melanoma drug therapy"', query time: 1.27s Refine Results
1
Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports

Authors: Haithem Chtioui, Laura Marino, Marco Zezza, Carine Mekoguem, Christophe Kosinski, Nelly Pitteloud, Faiza Lamine

Source: BMC Endocrine Disorders, Vol 19, Iss 1, Pp 1-5 (2019)
BMC Endocrine Disorders
BMC endocrine disorders, vol. 19, no. 1, pp. 144

Subject Terms: Immune checkpoint inhibitor, Autoimmune adverse events, Endocrinopathies, Type 1 diabetes, lcsh:Diseases of the endocrine glands. Clinical endocrinology, lcsh:RC648-665, Case Report, General Medicine, Endocrinology, Diabetes and Metabolism, Oncology, medicine.medical_specialty, medicine, Type 2 Diabetes Mellitus, Combination therapy, Type 2 diabetes, medicine.disease, business.industry, business, Ipilimumab, medicine.drug, Nivolumab, Diabetic ketoacidosis, Diabetes mellitus, Internal medicine, Acute Disease, Aged, 80 and over, Antineoplastic Agents, Immunological/administration & dosage, Antineoplastic Agents, Immunological/adverse effects, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Diabetes Mellitus, Type 1/chemically induced, Diabetes Mellitus, Type 1/diagnosis, Diabetes Mellitus, Type 1/pathology, Female, Humans, Ipilimumab/administration & dosage, Ipilimumab/adverse effects, Male, Melanoma/drug therapy, Melanoma/pathology, Middle Aged, Nivolumab/administration & dosage, Nivolumab/adverse effects, Skin Neoplasms/drug therapy, Skin Neoplasms/pathology

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a722f98fa2436ff73199210f96e9153
https://doaj.org/article/5e85b5b762c841489b8519ccf9b5cc94

HTML Full Text     PDF Full Text
2
Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology

Authors: Mounir Trimech, Olivier Michielin, Vincent Zoete, Krisztian Homicsko, Bettina Bisig, Fanny S Krebs, Alexandre Wicky, Camille Lea Gerard, Edoardo Missiaglia, Veronica Aedo-Lopez

Source: International Journal of Molecular Sciences, Vol 21, Iss 8021, p 8021 (2020)
International Journal of Molecular Sciences
International journal of molecular sciences, vol. 21, no. 21, pp. E8021
Volume 21
Issue 21

Subject Terms: precision oncology, molecular modelling, mutation, GNAQ, FGFR4, lcsh:Biology (General), lcsh:QH301-705.5, lcsh:Chemistry, lcsh:QD1-999, Article, Amino Acid Sequence, Antineoplastic Agents/therapeutic use, Female, GTP-Binding Protein alpha Subunits, Gq-G11/chemistry, GTP-Binding Protein alpha Subunits, Gq-G11/genetics, GTP-Binding Protein alpha Subunits, Gq-G11/metabolism, Humans, Melanoma/drug therapy, Melanoma/genetics, Melanoma/metabolism, Melanoma/pathology, Middle Aged, Models, Molecular, Mutant Proteins/chemistry, Mutant Proteins/genetics, Mutant Proteins/metabolism, Mutation, Protein Conformation, Protein Stability, Pyridones/therapeutic use, Pyrimidinones/therapeutic use, Receptor, Fibroblast Growth Factor, Type 4/chemistry, Receptor, Fibroblast Growth Factor, Type 4/genetics, Receptor, Fibroblast Growth Factor, Type 4/metabolism, Sequence Homology, Signal Transduction, Uveal Neoplasms/drug therapy, Uveal Neoplasms/genetics, Uveal Neoplasms/metabolism, Uveal Neoplasms/pathology, Inorganic Chemistry, Organic Chemistry, Physical and Theoretical Chemistry, Computer Science Applications, Spectroscopy, Molecular Biology, General Medicine, Catalysis, Gq alpha subunit, biology.protein, biology, Fibroblast growth factor receptor 4, Cancer research, Chemistry, Personalized oncology, MEK inhibitor, Trametinib, Melanoma, medicine.disease, medicine, medicine.disease_cause

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a720d088a79814508b85a7b35f96730d
https://www.mdpi.com/1422-0067/21/21/8021

3
Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient

Authors: Pillonel, Vincent, Dunet, Vincent, Hottinger, Andreas F., Berthod, Gregoire, Schiappacasse, Luis, Peters, Solange, Michielin, Olivier, Aedo-Lopez, Veronica

Source: Journal for immunotherapy of cancer, vol. 7, no. 1, pp. 336
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-6 (2019)
Journal for Immunotherapy of Cancer

Subject Terms: Adult, Antineoplastic Agents, Immunological/administration & dosage, Antineoplastic Agents, Immunological/adverse effects, Asymptomatic Diseases, Demyelinating Diseases/diagnosis, Demyelinating Diseases/etiology, Humans, Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Male, Melanoma/complications, Melanoma/diagnosis, Melanoma/drug therapy, Nivolumab/administration & dosage, Nivolumab/adverse effects, Remission, Spontaneous, CNS demyelination, Immune checkpoint inhibitors, Immune related adverse events, Metastatic melanoma, Neurological toxicities, Nivolumab, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, Case Report, Cancer Research, Pharmacology, Oncology, Molecular Medicine, Immunology, Immunology and Allergy, Internal medicine, medicine.medical_specialty, medicine, business.industry, business, Spontaneous remission, Hyperintensity, Immunotherapy, medicine.medical_treatment, Asymptomatic, medicine.symptom, Melanoma, medicine.disease

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::405a051ce719beb9bfa688acb52fdc90
https://serval.unil.ch/notice/serval:BIB_9C48A9CE403D

4
Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression

Authors: Molnár, Eszter, Garay, Tamás, Donia, Marco, Baranyi, Marcell, Rittler, Dominika, Berger, Walter, Tímár, József, Grusch, Michael, Hegedűs, Balázs

Source: International Journal of Molecular Sciences
Volume 20
Issue 18
International Journal of Molecular Sciences, Vol 20, Iss 18, p 4484 (2019)
Molnár, E, Garay, T, Donia, M, Baranyi, M, Rittler, D, Berger, W, Tímár, J, Grusch, M & Hegedűs, B 2019, ' Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma : Increased Cell Migration and Its Association with EGFR Expression ', International Journal of Molecular Sciences, vol. 20, no. 18, 4484 . https://doi.org/10.3390/ijms20184484

Subject Terms: melanoma, V600E BRAF mutation, vemurafenib resistance, EGFR, PD-L1, migration, Article, Inorganic Chemistry, Organic Chemistry, Physical and Theoretical Chemistry, Computer Science Applications, Spectroscopy, Molecular Biology, General Medicine, Catalysis, Microphthalmia-associated transcription factor, Vemurafenib, medicine.drug, medicine, Chemistry, Cancer research, Melanoma, medicine.disease, V600E, Cell migration, MAPK/ERK pathway, EGFR inhibitors, Epidermal growth factor receptor, biology.protein, biology, lcsh:Biology (General), lcsh:QH301-705.5, lcsh:Chemistry, lcsh:QD1-999, Adult, Aged, Cell Line, Tumor, Cell Movement/drug effects, Cell Proliferation/drug effects, Drug Resistance, Neoplasm/drug effects, Epithelial-Mesenchymal Transition/drug effects, ErbB Receptors/metabolism, Erlotinib Hydrochloride/pharmacology, Female, Gene Expression Regulation, Neoplastic/drug effects, Humans, Inhibitory Concentration 50, Male, Melanoma/drug therapy, Middle Aged, Mutation/genetics, Neoplasm Proteins/genetics, Phenotype, Proto-Oncogene Proteins B-raf/genetics, RNA, Messenger/genetics, Signal Transduction/drug effects, Time Factors, Vemurafenib/pharmacology, Journal Article, neoplasms, skin and connective tissue diseases, digestive system diseases

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c940f3bdc729af27e2d11c9360835c4c

HTML Full Text     PDF Full Text
5
An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell death markers in human cancer cells and dendritic cell activation

Authors: Castiello, Luciano, Zevini, Alessandra, Vulpis, Elisabetta, Muscolini, Michela, Ferrari, Matteo, Palermo, Enrico, Peruzzi, Giovanna, Krapp, Christian, Jakobsen, Martin, Olagnier, David, Zingoni, Alessandra, Santoni, Angela, Hiscott, John

Source: Castiello, L, Zevini, A, Vulpis, E, Muscolini, M, Ferrari, M, Palermo, E, Peruzzi, G, Krapp, C, Jakobsen, M, Olagnier, D, Zingoni, A, Santoni, A & Hiscott, J 2019, ' An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell death markers in human cancer cells and dendritic cell activation ', Cancer Immunology, Immunotherapy, vol. 68, no. 9, pp. 1479-1492 . https://doi.org/10.1007/s00262-019-02380-2

Subject Terms: Cancer Research, Oncology, Immunology, Immunology and Allergy, Cell, medicine.anatomical_structure, medicine, Cancer immunotherapy, medicine.medical_treatment, Immune system, Immunogenic cell death, Cancer research, Dendritic cell, Chemistry, CD80, CD86, Cancer cell, RIG-I, Interferons, Dendritic cells, ANTIVIRAL RESPONSE, INTERFERON, SUPPRESSION, BLOCKADE, DEFECTS, Caspase 3/metabolism, Humans, Antigen Presentation/drug effects, DEAD Box Protein 58/antagonists & inhibitors, Calreticulin/metabolism, Molecular Targeted Therapy, Alarmins/immunology, Antineoplastic Agents/pharmacology, Nelfinavir/analogs & derivatives, Melanoma/drug therapy, Cell Differentiation, Apoptosis Regulatory Proteins/metabolism, Interferons/metabolism, Immunization, Signal Transduction, Apoptosis/drug effects, Proto-Oncogene Proteins/metabolism, HMGB1 Protein/metabolism, Cell Line, Tumor, Dendritic Cells/immunology, Proto-Oncogene Proteins c-bcl-2/metabolism, chemical and pharmacologic phenomena

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a021b4cf5bcdbe0488874886620a2142

7
Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma

Authors: Lisbet Hölmich Rosenkrantz, Jon Bjoern, Inge Marie Svane, Rikke Andersen, Rikke Birgitte Lyngaa, Marco Donia, Sine Reker Hadrup

Source: Oncotarget
Bjoern, J, Lyngaa, R, Andersen, R, Rosenkrantz, L H, Hadrup, S R, Donia, M & Svane, I M 2017, ' Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma ', OncoTarget, vol. 8, no. 16, pp. 27062-27074 . https://doi.org/10.18632/oncotarget.16003
Bjørn, J, Lyngaa, R B, Andersen, R, Rosenkrantz, L H, Hadrup, S R, Donia, M & Svane, I M 2017, ' Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma ', OncoTarget, vol. 8, no. 16, pp. 27062-27074 . https://doi.org/10.18632/oncotarget.16003

Subject Terms: Research Paper, melanoma, tumour infiltrating lymphocyte, ipilimumab, CTLA-4, immunotherapy, Adult, Aged, Antineoplastic Agents, Immunological/pharmacology, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Biomarkers, CTLA-4 Antigen/antagonists & inhibitors, Female, Humans, Immunomodulation/drug effects, Ipilimumab/pharmacology, Lymphocyte Activation/drug effects, Lymphocytes, Tumor-Infiltrating/drug effects, Male, Melanoma/drug therapy, Middle Aged, Neoplasm Grading, Neoplasm Staging, Phenotype, T-Cell Antigen Receptor Specificity/immunology, Journal Article, Oncology, Medicine, business.industry, business, Cell therapy, Melanoma, medicine.disease, Cancer, T cell, medicine.anatomical_structure, Antigen, Ipilimumab, medicine.drug, Immunotherapy, medicine.medical_treatment, Immunology

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7471d7341b5e1be9ac8c2d2d2b691f5a
http://europepmc.org/articles/PMC5432318

8
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

Authors: Meyer, Christiane, Cagnon, Laurène, Costa-Nunes, Carla M., Baumgaertner, Petra, Montandon, Nicole, Leyvraz, Loredana, Michielin, Olivier, Romano, Emanuela, Speiser, Daniel E.

Source: Cancer immunology immunotherapy : CII
Cancer Immunology, Immunotherapy : Cii, vol. 63, no. 3, pp. 247-257

Subject Terms: Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal/administration & dosage, Antigens, CD14/metabolism, Biomarkers, Pharmacological, Cell Count, Female, Humans, Immune Tolerance, Male, Melanoma/blood, Melanoma/drug therapy, Middle Aged, Myeloid Cells/drug effects, Myeloid Cells/immunology, Neoplasm Metastasis, Neoplasm Staging, Skin Neoplasms/blood, Skin Neoplasms/drug therapy, Treatment Outcome, Young Adult, Cancer Research, Oncology, Immunology, Immunology and Allergy, medicine.medical_specialty, medicine, Biomarker (medicine), Clinical trial, Myeloid, medicine.anatomical_structure, Chemotherapy, medicine.medical_treatment, Internal medicine, Melanoma, medicine.disease, CTLA-4, Predictive marker, Ipilimumab, medicine.drug, business.industry, business

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c56423c16e80bb680b88c31ee7424759
http://doc.rero.ch/record/325855/files/262_2013_Article_1508.pdf

9
Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort

Authors: Marie-Thérèse Leccia, Brigitte Dreno, Marie Beylot-Barry, F. Brunet-Possenti, B. Oriano, Pierre-Emmanuel Stoebner, Jean-Philippe Lacour, Raphaël Porcher, Pauline Tétu, Stéphane Dalle, C. Allayous, Julie De Quatrebarbes, Laurent Mortier, Sophie Dalac, Sameh Mohamed, Caroline Dutriaux, Bernard Guillot, Celeste Lebbe, Thierry Lesimple, A. Ballon, Philippe Saiag, François Aubin, D. Legoupil

Contributors: Immunologie humaine, physiopathologie & immunithérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Centre de Diagnostic et de Thérapeutique, Hôpital de l’Hôtel-Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de Cytogénétique Constitutionnelle [Hospices civils de Lyon], Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Universitaire [Grenoble] (CHU), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CHU Bordeaux [Bordeaux], Service de Dermatologie [Nice], Hôpital Archet 2 [Nice] (CHU), Hôpital Ambroise Paré [AP-HP], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Hôpital Morvan - CHRU de Brest (CHU - BREST ), Centre Eugène Marquis (CRLCC), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Centre hospitalier universitaire de Nantes (CHU Nantes), Service de biostatistique et information médicale de l’hôpital Saint Louis (Equipe ECSTRA) (SBIM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut national du cancer [Boulogne] (INCA)-Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université de Paris (UP)

Source: European Journal of Cancer
European Journal of Cancer, Elsevier, 2019, 112, pp.38-46. ⟨10.1016/j.ejca.2019.02.009⟩

Subject Terms: Advanced melanoma, Brain metastases, Immunotherapy, Propensity score, Radiotherapy, Targeted therapy, MESH: Brain Neoplasms/radiotherapy, Melanoma/drug therapy, Melanoma/radiotherapy, Middle Aged, [SDV.CAN]Life Sciences [q-bio]/Cancer, Cancer Research, Oncology, Internal medicine, medicine.medical_specialty, medicine, Response rate (survey), Propensity score matching, Prospective cohort study, Confidence interval, Radiation therapy, medicine.medical_treatment, business.industry, business, Melanoma, medicine.disease, Systemic therapy, genetic structures, cardiovascular diseases, circulatory and respiratory physiology, cardiovascular system, equipment and supplies

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4740f4de3a0995fc1c93c6462b8f58e5
https://hal.umontpellier.fr/hal-02872129

10
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients

Authors: Fässler, Mirjam, Diem, Stefan, Mangana, Joanna, Hasan Ali, Omar, Berner, Fiamma, Bomze, David, Ring, Sandra, Niederer, Rebekka, del Carmen Gil Cruz, Cristina, Pérez Shibayama, Christian Ivan, Krolik, Michal, Siano, Marco, Joerger, Markus, Recher, Mike, Risch, Lorenz, Güsewell, Sabine, Risch, Martin, Speiser, Daniel E., Ludewig, Burkhard, Levesque, Mitchell P., Dummer, Reinhard, Flatz, Lukas

Source: Journal for immunotherapy of cancer, vol. 7, no. 1, pp. 50
Fässler, Mirjam; Diem, Stefan; Mangana, Joanna; Hasan Ali, Omar; Berner, Fiamma; Bomze, David; Ring, Sandra; Niederer, Rebekka; Del Carmen Gil Cruz, Cristina; Pérez Shibayama, Christian Ivan; Krolik, Michal; Siano, Marco; Joerger, Markus; Recher, Mike; Risch, Lorenz; Güsewell, Sabine; Risch, Martin; Speiser, Daniel E; Ludewig, Burkhard; Levesque, Mitchell P; Dummer, Reinhard; Flatz, Lukas (2019). Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. Journal for ImmunoTherapy of Cancer, 7:50.
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Journal for Immunotherapy of Cancer

Subject Terms: Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized/therapeutic use, Antibodies, Neoplasm/blood, Antineoplastic Agents, Immunological/therapeutic use, Biomarkers, Female, Humans, Immunoglobulin G/blood, Ipilimumab/therapeutic use, Male, Melanoma/blood, Melanoma/drug therapy, Melanoma/immunology, Middle Aged, Nivolumab/therapeutic use, Antibodies, Biomarker, Cancer/testis antigens, Checkpoint inhibitors, Immune response, MART1, Melanocyte differentiation antigens, Metastatic melanoma, NY-ESO-1, TRP1, TRP2, gp100, Dermatology Clinic, 610 Medicine & health, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, Research Article, Cancer Research, Pharmacology, Oncology, Molecular Medicine, Immunology, Immunology and Allergy, medicine.medical_specialty, medicine, Prospective cohort study, Internal medicine, business.industry, business, Glycoprotein 100, Biomarker (medicine), Melanocyte differentiation, Melanoma, medicine.disease, Cohort, Antigen

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3e25152da9d5985821b33a192b0f279
https://serval.unil.ch/notice/serval:BIB_98F688A29D1B

11
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma:Results From the Phase IIIb/IV CheckMate 511 Trial

Authors: Lebbé, Celeste, Meyer, Nicolas, Mortier, Laurent, Marquez-Rodas, Ivan, Robert, Caroline, Rutkowski, Piotr, Menzies, Alexander M., Eigentler, Thomas, Ascierto, Paolo A., Smylie, Michael, Schadendorf, Dirk, Ajaz, Mazhar, Svane, Inge Marie, Gonzalez, Rene, Rollin, Linda, Lord-Bessen, Jennifer, Saci, Abdel, Grigoryeva, Elena, Pigozzo, Jacopo

Source: Lebbé, C, Meyer, N, Mortier, L, Marquez-Rodas, I, Robert, C, Rutkowski, P, Menzies, A M, Eigentler, T, Ascierto, P A, Smylie, M, Schadendorf, D, Ajaz, M, Svane, I M, Gonzalez, R, Rollin, L, Lord-Bessen, J, Saci, A, Grigoryeva, E & Pigozzo, J 2019, ' Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma : Results From the Phase IIIb/IV CheckMate 511 Trial ', Journal of Clinical Oncology, vol. 37, no. 11, pp. 867-875 . https://doi.org/10.1200/JCO.18.01998
Journal of Clinical Oncology

Subject Terms: Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Disease Progression, Double-Blind Method, Drug Administration Schedule, Female, Humans, Ipilimumab/administration & dosage, Male, Melanoma/drug therapy, Middle Aged, Neoplasm Staging, Nivolumab/administration & dosage, Progression-Free Survival, Skin Neoplasms/drug therapy, Time Factors, Young Adult, Clinical Trial, Phase III, Clinical Trial, Phase IV, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Rapid Communication, Melanoma, Cancer Research, Oncology, Clinical endpoint, Ipilimumab, medicine.drug, medicine, Internal medicine, medicine.medical_specialty, Clinical trial, Nivolumab, Dosing, business.industry, business, Progression-free survival, Randomized controlled trial, law.invention, law, Gastroenterology, Adverse effect

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7100d36b125a105d0de169d7144e1e3e
https://curis.ku.dk/ws/files/236508642/jco.18.01998.pdf

13
The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England

Authors: Meng, Yang, Hertel, Nadine, Ellis, John, Morais, Edith, Johnson, Helen, Philips, Zoe, Roskell, Neil, Walker, Andrew, Lee, Dawn

Source: Meng, Y, Hertel, N, Ellis, J, Morais, E, Johnson, H, Philips, Z, Roskell, N, Walker, A & Lee, D 2018, ' The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England ', The European Journal of Health Economics, vol. 19, no. 8, pp. 1163-1172 . https://doi.org/10.1007/s10198-018-0964-4

Subject Terms: Health Policy, Economics, Econometrics and Finance (miscellaneous), Dacarbazine, medicine.drug, medicine, Ipilimumab, Survival analysis, Vemurafenib, Cost effectiveness, business.industry, business, Oncology, medicine.medical_specialty, Nivolumab, Dabrafenib, Clinical trial, Internal medicine, Age Factors, Aged, Antineoplastic Agents, Immunological/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/economics, Cost-Benefit Analysis, Dacarbazine/economics, Disease Progression, Disease-Free Survival, Female, Health Expenditures, Health Resources/economics, Humans, Imidazoles/economics, Ipilimumab/economics, Kaplan-Meier Estimate, Male, Markov Chains, Melanoma/drug therapy, Middle Aged, Models, Economic, Nivolumab/administration & dosage, Oximes/economics, Proto-Oncogene Proteins B-raf/genetics, Quality-Adjusted Life Years, Sex Factors, Skin Neoplasms/drug therapy, Vemurafenib/economics

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbba7ec0a8309e03b0b8e6ffb8f01a95

15
Calcium electroporation for treatment of cutaneous metastases; a randomized double-blinded phase II study, comparing the effect of calcium electroporation with electrochemotherapy

Authors: Falk, H., Matthiessen, L.W., Wooler, G., Gehl, J.

Source: Falk, H, Matthiessen, L W, Wooler, G & Gehl, J 2018, ' Calcium electroporation for treatment of cutaneous metastases; a randomized double-blinded phase II study, comparing the effect of calcium electroporation with electrochemotherapy ', Acta Oncologica, vol. 57, no. 3, pp. 311-319 . https://doi.org/10.1080/0284186X.2017.1355109

Subject Terms: Aged, Aged, 80 and over, Antineoplastic Agents/administration & dosage, Bleomycin/administration & dosage, Breast Neoplasms/drug therapy, Calcium/administration & dosage, Double-Blind Method, Electrochemotherapy/adverse effects, Female, Humans, Melanoma/drug therapy, Middle Aged, Skin Neoplasms/drug therapy, Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Radiology Nuclear Medicine and imaging, Oncology, Hematology, General Medicine, Phases of clinical research, Cancer research, Electroporation, Breast cancer, medicine.disease, medicine, Melanoma, Calcium, chemistry.chemical_element, chemistry, Bleomycin, chemistry.chemical_compound, business.industry, business, Pathology, medicine.medical_specialty, Electrochemotherapy, Biopsy, medicine.diagnostic_test

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81f142b9dd018e6f879cfdc3d3ab4247
https://curis.ku.dk/portal/da/publications/calcium-electroporation-for-treatment-of-cutaneous-metastases-a-randomized-doubleblinded-phase-ii-study-comparing-the-effect-of-calcium-electroporation-with-electrochemotherapy(933609c7-fc86-41c2-b535-5202dd039f05).html

16
Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

Authors: Rahima Jamal, Réjean Lapointe, Eftihia Cocolakis, Paméla Thébault, Shirin Kazemi, Jennifer E. Friedmann, Jeanne Dionne, Jean-François Cailhier, Karl Bélanger, Jean-Pierre Ayoub, Huy Le, Caroline Lambert, Jida El-Hajjar, Léon C. van Kempen, Alan Spatz, Wilson H. Miller

Source: Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, 5(1):83. BMC
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-13 (2017)

Subject Terms: Cancer Research, Pharmacology, Oncology, Molecular Medicine, Immunology, Immunology and Allergy, Internal medicine, medicine.medical_specialty, medicine, Immunotherapy, medicine.medical_treatment, Blockade, business.industry, business, Ipilimumab, medicine.drug, Immune system, Melanoma, medicine.disease, Carboplatin, chemistry.chemical_compound, chemistry, Paclitaxel, Chemotherapy, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/pharmacology, Carboplatin/pharmacology, Female, Humans, Ipilimumab/pharmacology, Male, Melanoma/drug therapy, Middle Aged, Neoplasm Staging, Paclitaxel/pharmacology, Skin Neoplasms/drug therapy, Treatment Outcome, Research Article, Chemokines, Immune score, B lymphocytes, PD-1, Predictive Biomarkers, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a997e0600263348fd01d8440e5c4d83

17
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland

Authors: Roger von Moos, Reinhard Dummer, Ralph P. Braun, Olivier Michielin, Ulrike Held, Mitchell P. Levesque, Corina Kaufmann, Joanna Mangana, Viola Stögner, Phil F. Cheng, Simone M. Goldinger, Valerie C Amann, Anna L. Frauchiger

Source: Melanoma research, vol. 27, no. 4, pp. 358-368
Mangana, Joanna; Cheng, Phil F; Kaufmann, Corina; Amann, Valerie C; Frauchiger, Anna L; Stögner, Viola; Held, Ulrike; von Moos, Roger; Michielin, Olivier; Braun, Ralph P; Levesque, Mitchell P; Goldinger, Simone M; Dummer, Reinhard (2017). Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. Melanoma research, 27(4):358-368.
Melanoma Research

Subject Terms: Antibodies, Monoclonal/therapeutic use, Cohort Studies, Humans, Immunotherapy/methods, Melanoma/drug therapy, Melanoma/pathology, Middle Aged, Retrospective Studies, Skin Neoplasms/drug therapy, Skin Neoplasms/pathology, Switzerland, Clinic and Policlinic for Internal Medicine, Epidemiology, Biostatistics and Prevention Institute (EBPI), Dermatology Clinic, 610 Medicine & health, Cancer Research, Dermatology, Oncology, Chemotherapy, medicine.medical_treatment, medicine, business.industry, business, Clinical trial, Cohort, Advanced melanoma, Surgery, medicine.medical_specialty, Immunotherapy, Targeted therapy, Aggressive disease, Internal medicine, Immune checkpoint inhibitors, ORIGINAL ARTICLES: Clinical research, melanoma, overall survival data, targeted therapy

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bbb70f561a7092d8ff26c9a75ab8148
https://serval.unil.ch/notice/serval:BIB_15F2678EE65F

18
Detailed imaging and genetic analysis reveal a secondaryBRAFL505Hresistance mutation and extensive intrapatient heterogeneity in metastaticBRAFmutant melanoma patients treated with vemurafenib

Authors: Nicolle Besselink, Emile E. Voest, Martijn P. Lolkema, Michael A. Hadders, Marlous Hoogstraat, Wouter B. Veldhuis, Thomas Kuilman, Marco J. Koudijs, Marijn van Stralen, Stefan M. Willems, Eelco F. J. Meijer, Daniel S. Peeper, Christa G. Gadellaa-van Hooijdonk, Edwin Cuppen, Inge Ubink, Oscar Krijgsman, Mark Pieterse

Contributors: PMB medici, Hubrecht Institute for Developmental Biology and Stem Cell Research

Source: Pigment Cell and Melanoma Research, 28(3), 318. Wiley-Blackwell
Pigment cell & melanoma research, 28(3), 318-23. Blackwell Publishing Ltd
Pigment Cell & Melanoma Research, 28(3), 318-23. Wiley-Blackwell

Subject Terms: Dermatology, General Biochemistry, Genetics and Molecular Biology, Oncology, Somatic evolution in cancer, Medicine, business.industry, business, Mutant, Vemurafenib, medicine.drug, Mutation, medicine.disease_cause, Melanoma, medicine.disease, Internal medicine, medicine.medical_specialty, Cancer, Imatinib, Resistance mutation, Bioinformatics, BRAF, vemurafenib, intratumoral heterogeneity, therapy resistance, volumetric imaging analysis, GASTROINTESTINAL STROMAL TUMOR, ACQUIRED-RESISTANCE, RAF INHIBITION, CLONAL EVOLUTION, KINASE DOMAIN, MECHANISMS, IDENTIFICATION, IMATINIB, CANCER, DISPARITY, Journal Article, Research Support, Non-U.S. Gov't, Biopsy, Diagnostic Imaging, Drug Resistance, Neoplasm/drug effects, Genetic Heterogeneity, Humans, Indoles/pharmacology, Melanoma/drug therapy, Mutation/genetics, Neoplasm Metastasis, Proto-Oncogene Proteins B-raf/genetics, Sulfonamides/pharmacology, Drug Resistance, Neoplasm/drug effects, Research Support, Non-U.S. Gov't

File Description: image/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f1b0f5e023cd8632c197672f27722d2
https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fpcmr.12347

19
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

Authors: Sun, Chong, Wang, Liqin, Huang, Sidong, Heynen, Guus J J E, Prahallad, Anirudh, Robert, Caroline, Haanen, John, Blank, Christian, Wesseling, Jelle, Willems, Stefan M, Zecchin, Davide, Hobor, Sebastijan, Bajpe, Prashanth K, Lieftink, Cor, Mateus, Christina, Vagner, Stephan, Grernrum, Wipawadee, Hofland, Ingrid, Schlicker, Andreas, Wessels, Lodewyk F A, Beijersbergen, Roderick L, Bardelli, Alberto, Di Nicolantonio, Federica, Eggermont, Alexander M M, Bernards, Rene

Contributors: PMB medici

Source: Nature, 508(7494), 118-22. Nature Publishing Group

Subject Terms: Animals, Antineoplastic Agents/administration & dosage, Cell Proliferation/drug effects, Cellular Senescence/drug effects, Drug Resistance, Neoplasm/drug effects, ErbB Receptors/biosynthesis, Female, Flow Cytometry, Gene Expression Regulation, Neoplastic/drug effects, Gene Library, Humans, Indoles/administration & dosage, Melanoma/drug therapy, Mice, Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors, Protein Kinase Inhibitors/administration & dosage, Proto-Oncogene Proteins B-raf/antagonists & inhibitors, RNA, Small Interfering, Receptor Protein-Tyrosine Kinases/biosynthesis, Receptor, Platelet-Derived Growth Factor beta/biosynthesis, SOXE Transcription Factors/deficiency, Signal Transduction/drug effects, Sulfonamides/administration & dosage, Transforming Growth Factor beta/metabolism, Vemurafenib, Multidisciplinary, Drug resistance, V600E, Cancer research, Small hairpin RNA, Biology, medicine.drug, medicine, Growth factor receptor, Melanoma, medicine.disease, PDGFRB, Epidermal growth factor receptor, biology.protein, Drug Resistance, Neoplasm/drug effects, Gene Expression Regulation, Neoplastic/drug effects, RNA, Small Interfering, Receptor, Platelet-Derived Growth Factor beta/biosynthesis, neoplasms

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5b63cfde6924d5a39c6b040a57884b4

PDF Full Text
20
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential

Authors: Wang, Liqin, Leite de Oliveira, Rodrigo, Huijberts, Sanne, Bosdriesz, Evert, Pencheva, Nora, Brunen, Diede, Bosma, Astrid, Song, Ji-Ying, Zevenhoven, John, Los-de Vries, G Tjitske, Horlings, Hugo, Nuijen, Bastiaan, Beijnen, Jos H, Schellens, Jan H M, Bernards, Rene

Contributors: Internal medicine, Public and occupational health, Pathology, Bioinformatics

Source: Cell, 173(6), 1413-1425.e14. Cell Press
Cell, 173(6), 1413

Subject Terms: Amino Acid Transport System y+/metabolism, Animals, Apoptosis, Cell Line, Tumor, Cell Proliferation, Drug Resistance, Neoplasm, Gene Expression Regulation, Neoplastic/drug effects, Histone Deacetylase Inhibitors/pharmacology, Humans, MAP Kinase Kinase 1/metabolism, MAP Kinase Signaling System, Melanoma/drug therapy, Mice, Mutation, Neoplasm Transplantation, Protein Kinase Inhibitors/pharmacology, Proto-Oncogene Proteins B-raf/genetics, Reactive Oxygen Species/metabolism, Skin Neoplasms/drug therapy, Treatment Outcome, Vorinostat/pharmacology, Cell Line, Tumor, Drug Resistance, Neoplasm, Gene Expression Regulation, Neoplastic/drug effects, General Biochemistry, Genetics and Molecular Biology, Vorinostat, medicine.drug, medicine, Cancer research, Drug resistance, V600E, MAPK/ERK pathway, Histone deacetylase inhibitor, medicine.drug_class, Melanoma, medicine.disease, Biology, Mitogen-activated protein kinase, biology.protein, neoplasms

File Description: image/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3421f6bf7b5c00b35cf4683a3d2f9800

Search Tools: Get RSS Feed — Email this Search